238 related articles for article (PubMed ID: 35378710)
21. Critical role of oncogenic KRAS in pancreatic cancer (Review).
Liu J; Ji S; Liang C; Qin Y; Jin K; Liang D; Xu W; Shi S; Zhang B; Liu L; Liu C; Xu J; Ni Q; Yu X
Mol Med Rep; 2016 Jun; 13(6):4943-9. PubMed ID: 27121414
[TBL] [Abstract][Full Text] [Related]
22. MAP kinase and autophagy pathways cooperate to maintain RAS mutant cancer cell survival.
Lee CS; Lee LC; Yuan TL; Chakka S; Fellmann C; Lowe SW; Caplen NJ; McCormick F; Luo J
Proc Natl Acad Sci U S A; 2019 Mar; 116(10):4508-4517. PubMed ID: 30709910
[TBL] [Abstract][Full Text] [Related]
23. Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer.
Kamerkar S; LeBleu VS; Sugimoto H; Yang S; Ruivo CF; Melo SA; Lee JJ; Kalluri R
Nature; 2017 Jun; 546(7659):498-503. PubMed ID: 28607485
[TBL] [Abstract][Full Text] [Related]
24. KRAS Mutation Variants and Co-occurring PI3K Pathway Alterations Impact Survival for Patients with Pancreatic Ductal Adenocarcinomas.
Diehl AC; Hannan LM; Zhen DB; Coveler AL; King G; Cohen SA; Harris WP; Shankaran V; Wong KM; Green S; Ng N; Pillarisetty VG; Sham JG; Park JO; Reddi D; Konnick EQ; Pritchard CC; Baker K; Redman M; Chiorean EG
Oncologist; 2022 Dec; 27(12):1025-1033. PubMed ID: 36124727
[TBL] [Abstract][Full Text] [Related]
25. Targeting the Oncogene KRAS Mutant Pancreatic Cancer by Synergistic Blocking of Lysosomal Acidification and Rapid Drug Release.
Kong C; Li Y; Liu Z; Ye J; Wang Z; Zhang L; Kong W; Liu H; Liu C; Pang H; Hu Z; Gao J; Qian F
ACS Nano; 2019 Apr; 13(4):4049-4063. PubMed ID: 30912923
[TBL] [Abstract][Full Text] [Related]
26. Loss of Somatostatin Receptor Subtype 2 Promotes Growth of KRAS-Induced Pancreatic Tumors in Mice by Activating PI3K Signaling and Overexpression of CXCL16.
Chalabi-Dchar M; Cassant-Sourdy S; Duluc C; Fanjul M; Lulka H; Samain R; Roche C; Breibach F; Delisle MB; Poupot M; Dufresne M; Shimaoka T; Yonehara S; Mathonnet M; Pyronnet S; Bousquet C
Gastroenterology; 2015 Jun; 148(7):1452-65. PubMed ID: 25683115
[TBL] [Abstract][Full Text] [Related]
27. Personalizing
Falcomatà C; Schneider G; Saur D
Cancer Discov; 2020 Jan; 10(1):23-25. PubMed ID: 31919121
[No Abstract] [Full Text] [Related]
28. RAS-Driven Macropinocytosis of Albumin or Dextran Reveals Mutation-Specific Target Engagement of RAS p.G12C Inhibitor ARS-1620 by NIR-Fluorescence Imaging.
Sutton MN; Gammon ST; Muzzioli R; Pisaneschi F; Radaram B; Yang P; Piwnica-Worms D
Mol Imaging Biol; 2022 Jun; 24(3):498-509. PubMed ID: 34905147
[TBL] [Abstract][Full Text] [Related]
29. KRAS mutation in pancreatic cancer.
Luo J
Semin Oncol; 2021 Feb; 48(1):10-18. PubMed ID: 33676749
[TBL] [Abstract][Full Text] [Related]
30. Cryptotanshinone suppresses tumorigenesis by inhibiting lipogenesis and promoting reactive oxygen species production in KRAS‑activated pancreatic cancer cells.
Terado T; Kim CJ; Ushio A; Minami K; Tambe Y; Kageyama S; Kawauchi A; Tsunoda T; Shirasawa S; Tanaka H; Inoue H
Int J Oncol; 2022 Sep; 61(3):. PubMed ID: 35894141
[TBL] [Abstract][Full Text] [Related]
31. Insulin promotes invasion and migration of KRAS
Wang G; Yin L; Peng Y; Gao Y; Gao H; Zhang J; Lv N; Miao Y; Lu Z
Cell Prolif; 2019 May; 52(3):e12575. PubMed ID: 30838710
[TBL] [Abstract][Full Text] [Related]
32. The type of KRAS mutation drives PI3Kα/γ signalling dependency: Implication for the choice of targeted therapy in pancreatic adenocarcinoma patients.
Cayron C; Guillermet-Guibert J
Clin Res Hepatol Gastroenterol; 2021 Jan; 45(1):101473. PubMed ID: 32593694
[TBL] [Abstract][Full Text] [Related]
33. A recombinant chimeric protein specifically induces mutant KRAS degradation and potently inhibits pancreatic tumor growth.
Pan T; Zhang Y; Zhou N; He X; Chen C; Liang L; Duan X; Lin Y; Wu K; Zhang H
Oncotarget; 2016 Jul; 7(28):44299-44309. PubMed ID: 27322423
[TBL] [Abstract][Full Text] [Related]
34. Highlights on the Role of
Hafezi S; Saber-Ayad M; Abdel-Rahman WM
Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638560
[TBL] [Abstract][Full Text] [Related]
35. Impact of Oncogenic Changes in p53 and KRAS on Macropinocytosis and Ferroptosis in Colon Cancer Cells and Anticancer Efficacy of Niclosamide with Differential Effects on These Two Processes.
Nguyen NT; Sennoune SR; Dharmalingam-Nandagopal G; Sivaprakasam S; Bhutia YD; Ganapathy V
Cells; 2024 May; 13(11):. PubMed ID: 38891084
[TBL] [Abstract][Full Text] [Related]
36. Transcription Factor Eb Is Required for Macropinocytosis-Mediated Growth Recovery of Nutrient-Deprived Kras-Mutant Cells.
Jeong S; Byun JK; Cho SJ; Chin J; Lee IK; Choi YK; Park KG
Nutrients; 2018 Nov; 10(11):. PubMed ID: 30400219
[TBL] [Abstract][Full Text] [Related]
37. Targeting metabolic reprogramming in KRAS-driven cancers.
Kawada K; Toda K; Sakai Y
Int J Clin Oncol; 2017 Aug; 22(4):651-659. PubMed ID: 28647837
[TBL] [Abstract][Full Text] [Related]
38. Roles of EGFR and KRAS and their downstream signaling pathways in pancreatic cancer and pancreatic cancer stem cells.
Fitzgerald TL; Lertpiriyapong K; Cocco L; Martelli AM; Libra M; Candido S; Montalto G; Cervello M; Steelman L; Abrams SL; McCubrey JA
Adv Biol Regul; 2015 Sep; 59():65-81. PubMed ID: 26257206
[TBL] [Abstract][Full Text] [Related]
39. Macropinocytic dextran facilitates KRAS-targeted delivery while reducing drug-induced tumor immunity depletion in pancreatic cancer.
Yuan F; Sun M; Liu Z; Liu H; Kong W; Wang R; Qian F
Theranostics; 2022; 12(3):1061-1073. PubMed ID: 35154474
[No Abstract] [Full Text] [Related]
40. Nicotine promotes initiation and progression of KRAS-induced pancreatic cancer via Gata6-dependent dedifferentiation of acinar cells in mice.
Hermann PC; Sancho P; Cañamero M; Martinelli P; Madriles F; Michl P; Gress T; de Pascual R; Gandia L; Guerra C; Barbacid M; Wagner M; Vieira CR; Aicher A; Real FX; Sainz B; Heeschen C
Gastroenterology; 2014 Nov; 147(5):1119-33.e4. PubMed ID: 25127677
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
